Дифференциальная диагностика рака поджелудочной железы и хронического псевдотуморозного панкреатита: обзор литературы

Каждый год случайно выявляется все больше поражений поджелудочной железы. Помимо генетической предрасположенности и факторов окружающей среды, хронический панкреатит, безусловно, является самым большим фактором риска развития злокачественной опухоли поджелудочной железы. В настоящее время отсутствуют методы скринига для  раннего выявления рака поджелудочной железы и его дифференциальной диагностики с хроническим панкреатитом. Точная характеристика поражений поджелудочной железы имеет решающее значение при принятии решения о том, следует ли использовать активную хирургическую тактику или динамическое наблюдение, какую выполнять операцию.

1. Каприн А. Д., Старинский В. В., Шахзадова А. О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П. А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.

2. Kennedy T., Preczewski L., Stocker S. J. et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience // Am J Surg. 2006. Vol. 191, № 3. P. 437–441.

3. Zakaria H. M., Mohamed A., Alsebaey A., Omar H., Elazab D., Gaballa N. K. Prognostic factors following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma // Int Surg J. 2018. Vol. 5, № 12. P. 3887–3882.

4. Lowenfels A. B., Maisonneuve P., Cavallini G., Ammann R. W., Lankisch P. G. et al. Pancreatitis and the risk of pancreatic cancer // International pancreatitis study group // N Engl J Med. 1993. Vol. 328. P. 1433–1437.

5. Talamini G., Falconi M., Bassi C., Sartori N., Salvia R. et al. Incidence of cancer in the course of chronic pancreatitis //Am J Gastroenterol. 1999. Vol. 94. P. 1253–1260.

6. Birgin E., Hablawetz P., Téoule P., Rückert F., Wilhelm T. J. Chronic pancreatitis and resectable synchronous pancreatic carcinoma: a survival analysis // Pancreatology. 2018. Vol. 18. P. 394–398.

7. Malinka T., Klein F., Le Thu T., Rösch C.S., Wundsam H. et al. A binational analysis of 252 pancreatic resections for chronic pancreatitis with regard to incidental carcinoma sequence and overall postoperative outcome // Anticancer Res. 2018. Vol. 38. P. 4947–4952.

8. Munigala S., Kanwal F., Xian H., Agarwal B. New diagnosis of chronic pancreatitis: risk of missing an underlying pancreatic cancer // American Journal of Gastroenterology. 2014. Vol. 109, № 11. P. 1824–1830.

9. Gheorghe G., Bungau S., Ilie M., Behl T., Vesa C. M. et al. Early diagnosis of pancreatic cancer: The key for survival // Diagnostics. 2020. Vol.10. P. 869. DOI: 10.3390/diagnostics10110869.

10. Gheorghe G., Diaconu C. C., Ionescu V., Constantinescu G., Bacalbasa N. et al. Risk factors for pancreatic cancer: Emerging Role of viral hepatitis // J. Pers. Med. 2022. Vol. 12. P. 83. DOI: 10.3390/jpm12010083.

11. Han M., Tran T. P. T., Oh J. K. Chronic pancreatitis and cancer risk in a matched cohort study using national claims data in South Korea // Sci. Rep. 2022. Vol.12. P. 5545. DOI: 10.1038/s41598-022-09426-z.

12. Ouyang G., Pan G., Liu Q., Wu Y., Liu Z. et al. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017 // BMC Med. 2020. Vol.18. P. 388. DOI: 10.1186/s12916-020-01859-5.

13. Olesen S. S., Mortensen L. H., Zinck E., Becker U., Drewes A. M. et al. Time trends in incidence and prevalence of chronic pancreatitis: A 25- year population-based nationwide study // United Eur. Gastroenterol. J. 2020. Vol. 9. P. 82–90. DOI: 10.1177/2050640620966513.

14. Kichler A., Jang S. Chronic pancreatitis: epidemiology, diagnosis, and management updates // Drugs. 2020. Vol. 80. P. 1155–1168. DOI: 10. 1007/s40265-020-01360-6.

15. Kirkegard J., Mortensen F. V., Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: A systematic review and meta-analysis // Am. J. Gastroenterol. 2017. Vol. 112. P. 1366–1372. DOI: 10.1038/ajg.2017.218.

16. Hollinshead K. E. R., Parker S. J., Eapen V. V., Encarnacion-Rosado J., Sohn A. et al. Respiratory supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer // Cell Rep. 2020. Vol. 33. P. 108231. DOI: 10.1016/j.celrep.2020.108231.

17. De La Cruz M. S., Young A. P., Ruffin M. T. Diagnosis and management of pancreatic cancer // Am. Fam. Physician. 2014. Vol. 89. P. 626–632.

18. Munigala S., Kanwal F., Xian H., Agarwal B. New diagnosis of chronic pancreatitis: Risk of missing an underlying pancreatic cancer // Am. J. Gastroenterol. 2014. Vol. 109. P. 1824–1830.

19. Kitano M., Yoshida T., Itonaga M., Tamura T., Hatamaru K., Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer // J Gastroenterol. 2019. Vol. 54. P. 19–32.

20. Schima W., Böhm G., Rösch C. S., Klaus A., Függer R., Kopf H. Massforming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation // Cancer Imaging. 2020. Vol. 20. P. 1–12.

21. Marrelli D., Caruso S., Pedrazzani C. et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions //Am J Surg. 2009. Vol. 198, № 3. P. 333–339.

22. Kim Y. C., Kim H. J., Park J. H. et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? // J Gastroenterol Hepatol. 2009. Vol. 24, № 12. P. 1869–1875.

23. Liao Q., Zhao Y. P., Wu W. W., Li B. L., Li J. Y. Diagnosis and treatment of chronic pancreatitis // Hepatobiliary Pancreat Dis Int. 2003. Vol. 2, № 3. P. 445–448.

24. Choueiri N. E., Balci N. C., Alkaade S., Burton F. R. Advanced imaging of chronic pancreatitis // Curr Gastroenterol Rep. 2010. Vol. 12, № 2. P. 114–120.

25. Oterdoom L. H., van Weyenberg S. J., de Boer N. K. Double-duct sign: do not forget the gallstones // J Gastrointestin Liver Dis. 2013. Vol. 22, № 4. P. 447–450.

26. Graziani R., Tapparelli M., Malagò R. et al. The various imaging aspects of chronic pancreatitis // JOP. 2005. Vol. 6, № 1, Suppl. P. 73–88.

27. Ichikawa T., Sou H., Araki T. et al. Duct-penetrating sign at MRCP: usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas // Radiology. 2001. Vol. 221, № 1. P. 107–116.

28. Sandrasegaran K., Nutakki K., Tahir B., Dhanabal A., Tann M., Gregory A. Use of diffusion-weighted MRI to differentiate chronic pancreatitis from pancreatic cancer // American Journal of Roentgenology. 2013. Vol. 201. P. 1002–1008.

29. Garcia T. S., Engelholm J. L., Vouche M., Hirakata V. N., Leitão C. B. Intra- and interobserver reproducibility of pancreatic perfusion by computed tomography // Sci Rep. 2019. Vol. 9, № 1. P. 6043. DOI: 10.1038/s41598-019-42519-w.

30. Li P., Deng W., Xue H., Xu K., Zhu L. et al. Weight-adapted ultra-low-dose pancreatic perfusion CT: radiation dose, image quality, and perfusion parameters // Abdom Radiol (NY). 2019. Vol. 44, № 6. P. 2196–2204. DOI: 10.1007/s00261-019-01938-z.

31. Singer E., Gschwantler M., Plattner D., Kriwanek S., Armbruster C. et al. Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera // Eur J Gastroenterol Hepatol. 2007. Vol. 19. P. 471–478.

32. Wang Y., Miller F. H., Chen Z. E., Merrick L., Mortele K. J. et al. Diffusionweighted MR imaging of solid and cystic lesions of the pancreas // RadioGraphics. 2011. Vol. 31, № 3. P. E47–E64.

33. Wei T., Zhang X., Zhang Q., Yang J., Chen Q. et al. Vimentin positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer // Cancer Lett. 2019. Vol. 452. P. 237.

34. Löhr M., Müller P., Mora J., Brinkmann B., Ostwald C. et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis // Gastrointest Endosc. 2001. Vol. 53. P. 734–743.

35. Liu X., Liu L., Ji Y., Li C., Wei T. et al. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer// EBioMedicine. 2019. Vol. 41. P. 345–56.

36. Radon T. P., Massat N. J., Jones R., Alrawashdeh W., Dumartin L. et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma // Clin Cancer Res. 2015. Vol. 21, № 15. P. 3512–21.

37. Zhang L., Farrell J. J., Zhou H., Elashoff D., Akin D. et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer // Gastroenterology. 2010. Vol. 138, № 3. P. 949–57.

38. Liu R., Chen X., Du Y., Yao W., Shen L. et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer // Clin Chem. 2012. Vol. 58, № 3. P. 610–8.

39. Nakamura S., Sadakari Y., Ohtsuka T., Okayama T., Nakashima Y. et al. Pancreatic juice exosomal MicroRNAs as biomarkers for detection of pancreatic ductal adenocarcinoma // Ann Surg Oncol. 2019. Vol. 26, № 7. P. 2104–11.